In addition to pancreatic cancer, validation studies are necessary for detecting driver mutations unique to other types of carcinomas, such as the BRAF V600E mutation observed during thyroid cancer29, as it would enhance the possibility of developing widespread clinical applications. Here, BRAF is linked to pancreatic neoplasm.